Swiss Nuclides

Before founding NUCLIDIUM in 2017, Leila was active as a programme manager in the worldwide development of infrastructure for radionuclide production. NUCLIDIUM collaborates actively with leading partners in a multitude of interdisciplinary fields – to optimise our production processes, further expand our supply network and advance our innovative product portfolio into the clinic. NUCLIDIUM’s mission is to provide personalised therapy for cancer patients at every stage of their disease. As CEO, Leila focuses on shaping and the execution of NUCLIDIUM`s international strategy towards its primary goal of improving the availability and affordability of radiopharmaceuticals in cancer diagnosis and therapy worldwide. Francesco has a broad knowledge in the production of radiopharmaceuticals, from radiolabelling to quality controls, following GMP principles. This includes the definition of product specifications, quality controls and the documentation of processes for the manufacturing of radionuclides and radiopharmaceuticals according to GMP principles. Markus is a physicist with conviction and training, holding a PhD in mechanical engineering from the University of Padua, specialising in metrology for precision metal additive manufacturing. This includes setting up new production sites, managing R&D projects, and analysing and evaluating research data paving the way for further improvement and development.